In the present study, no significant difference was found in survival according to the p15 expression level among all evaluable AML patients. Although we found no difference in survival according to the p15 expression level in patients with favorable cytogenetics, low p15 expression significantly correlated to unfavorable clinical outcome among the remaining 60 patients with intermediate or adverse cytogenetics. We previously reported that p15 inactivation by deletion and methylation was highly associated with poor DFS in adult patients with precursor B-cell acute lymphoblastic leukemia.
TO THE EDITOR
The p53 tumor suppressor is a transcription factor, which in response to various types of genotoxic stresses transactivates a number of genes by binding to specific DNA sequences. Somatic p53 mutations are the most frequent genetic alterations in human cancer. p53 mutations are uncommon in de novo acute myeloid leukemia (AML) and they seem to be restricted to particular cytogenetic subgroups with a very poor outcome. 1 The p53-induced gene 3 (PIG3) is activated upon overexpression of p53 and it has been implicated in the accumulation of reactive oxygen species and the induction of apoptosis.
2,3 p53 directly binds and activates the PIG3 promoter through a pentanucleotide microsatellite sequence (TGYCC)n. Contente et al 4 have found that the number of pentanucleotide repeats may be 10, 15, 16 or 17 with allelic frequencies of 5.1, 62, 21.4 and 11.5%, respectively. The number of pentanucleotide repeats correlated with the degree of transcriptional activation by p53. In order to assess the pentanucleotide PIG3 microsatellite allelic frequencies in AML, 138 adult de novo AML cases enrolled in different protocols were analyzed using the following fluorescent (NED) primers: GGG CGC TGC GGT GCC AGC CTG AG (forward) and ACC TTC AGG AGG ACT TCA CC (reverse).
3 PCR conditions were: one cycle of denaturation (941C for 1 min); 30 cycles of denaturation (941C for 30 s), annealing (571C for 30 s) and extension (721C for 40 s) with a final extension step at 721C for 10 min. Amplimers were further run in an ABIPRISM 310 (Applied Biosystems, Foster City, CA, USA) genetic analyzer. Allelic frequencies obtained for each repeat were as follows: 10 copies: 7.24%, 15 copies: 67.75%, 16 copies: 15.94% and 17 copies: 9.05%.
PIG3 microsatellite alleles were also analyzed using paired diagnosis and remission samples in 85 patients. Leukemic infiltration at diagnosis was always greater than 65% and remission samples (peripheral blood) had less that 1% of abnormal myeloid population assessed by flow cytometry. In four cases, a loss of heterozygosity (LOH) of the microsatellite in the PIG3 promoter was detected (Figure 1 ) (4.7%): three patients displayed a normal karyotype without 2p alterations and the remaining patient had a del 16(q25). One patient disclosed an FLT3 internal tandem duplication (ITD) and two showed a MLL rearrangement of the self-fusion type. All four cases presented a loss of the longer allele and consequently, the most effective in PIG3 induction (Table 1) . No p53 mutations were detected in those cases when exons 5-9 were analyzed.
It has been shown that a higher number of the pentanucleotide repeats correlates with a stronger responsiveness to p53 (4) . If LOH at the polymorphic PIG3 promoter really leads to a lower response to p53, these findings may reflect a selective advantage of the more resistant clone to the induction of apoptosis. Regulatory sequences of certain p53 responsive genes may be a recurrent target of genetic lesions during the leukemogenic process even in cases with a normal karyotype.
It should be investigated whether neoplastic cells with a single copy of the short microsatellite PIG3 promoter show clonal dominance and the mechanisms underlying the microdeletion process.
TNF-a receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells the unique ability to differentiate into leukemic DC, thereby conserving their intrinsic leukemia antigen repertoire and obtaining full potential of antigen presentation. We have shown that DC generated from acute myeloid leukemic (AML) blasts are able to initiate autologous cytotoxic T-cell responses, and thus hold promise for vaccination purposes in a minimal residual disease (MRD) status. 1 In a recently performed phase-I study on CML-DC vaccination in advanced stage chronic myeloid leukemia (CML), we were able to detect strong DTH-responses representing autologous CML-specific T-cell responses. The PIG3 polymorphic promoter shows LOH in de novo AML. Electropherograms obtained with labeled PCR products containing the PIG3 microsatellite (TGYCC)n. Top: sample obtained at diagnosis displayed a loss of the 17 repeats allelle (arrow). Bottom: sample obtained at remission. 
